Crystalys Therapeutics Announces $130 Million Series B Financing To Advance Gout Treatment Dotinurad
By Amit Chowdhry ● Jul 24, 2026
Crystalys Therapeutics Inc. announced the closing of an oversubscribed $130 million Series B financing to support late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once-daily, oral URAT1 inhibitor for the treatment of gout. The round was led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund, and a group of existing investors including Novo Holdings and SR One.